Details of the Drug-Related molecule(s) Interaction Atlas

Imidazo bicyclic iminium derivative 8 Drug Info

PMID25726713-Compound-76

Cross-matching ID

TTD Drug ID

DMBMFPC

General Information of Drug (ID: DMBMFPC)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Smoothened homolog (SMO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-04449913	DMSB068	Chronic myelomonocytic leukaemia	2A40	Approved	[2]
Vismodegib	DM5IXKQ	Basal cell carcinoma	2C32	Approved	[3]
LDE225	DMM9F25	Basal cell carcinoma	2C32	Phase 2	[4]
LY2940680	DMTJWIQ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
BMS-833923	DM459Q7	Solid tumour/cancer	2A00-2F9Z	Phase 1b	[5]
LEQ-506	DM5INZP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
TAK-441	DM7DFBL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
PMID25726713-Compound-49	DM2CT4G	N. A.	N. A.	Patented	[1]
PMID25726713-Compound-51	DMF0OW4	N. A.	N. A.	Patented	[1]
PMID25726713-Compound-48	DMSIOUA	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4	Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79.
5	Clinical pipeline report, company report or official report of Exelixis (2011).
6	Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5.
7	TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66.